VONTROL
LOE ApproachingNDAORALTABLET
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VONTROL is an oral small-molecule tablet approved by GSK in 1967 for an undisclosed indication. The mechanism of action and pharmacologic class are not publicly detailed in available data, limiting characterization of its therapeutic mechanism.
LOE Approaching
Approaching loss of exclusivity signals contraction; commercial teams likely downsizing or pivoting to line extensions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's late-life-cycle stage and minimal hiring activity. Roles on VONTROL are typically defensive, focused on market share retention and cost management rather than growth.
Brand ManagerField Sales Representative
Worked on VONTROL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.